Posted On: 09/29/2015 2:25:18 PM
Post# of 72447
Posted this on the other board. Just random speculation as to why Leo is quiet. My conclusion is that expanding K after phase 1 is going to be expensive and will require a partner.
9/08/15 PR - 1) Cellceutix "is pleased to announce that it will be concluding its Phase 1 trial of the novel compound Kevetrin in patients
with advanced solid tumors at the completion of the current cohort."
9/08/15 PR - 2) "With the conclusion of the Phase 1 trial, clinical development of Kevetrin is going to greatly expand and accelerate"
9/08/15 PR -3) Cellceutix also wishes to inform shareholders that it is preparing a proxy statement to be filed with the Securities and Exchange Commission for the Company’s first Annual General Meeting of Shareholders.
9/17/15 BH - "My birds have been telling me of significant meetings happening (or have happened) between leo and C level execs"
9/18/15 (via Sox) Leo- "we will be fighting back with strength", "I hope to sometime next week update shareholders and you will better understand."
9/08/15 PR - 1) Cellceutix "is pleased to announce that it will be concluding its Phase 1 trial of the novel compound Kevetrin in patients
with advanced solid tumors at the completion of the current cohort."
9/08/15 PR - 2) "With the conclusion of the Phase 1 trial, clinical development of Kevetrin is going to greatly expand and accelerate"
9/08/15 PR -3) Cellceutix also wishes to inform shareholders that it is preparing a proxy statement to be filed with the Securities and Exchange Commission for the Company’s first Annual General Meeting of Shareholders.
9/17/15 BH - "My birds have been telling me of significant meetings happening (or have happened) between leo and C level execs"
9/18/15 (via Sox) Leo- "we will be fighting back with strength", "I hope to sometime next week update shareholders and you will better understand."
(0)
(0)
